TherapeuticsMD, Inc. (NASDAQ:TXMD) Short Interest Update

TherapeuticsMD, Inc. (NASDAQ:TXMD) saw a large decline in short interest during the month of January. As of January 15th, there was short interest totalling 12,000 shares, a decline of 43.7% from the December 31st total of 21,300 shares. Currently, 0.1% of the shares of the company are sold short. Based on an average daily trading volume, of 275,000 shares, the days-to-cover ratio is currently 0.0 days.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on shares of TherapeuticsMD in a report on Tuesday, January 14th. They set a “hold” rating for the company.

TherapeuticsMD Price Performance

TherapeuticsMD stock traded down $0.01 during trading on Friday, hitting $1.07. The stock had a trading volume of 11,061 shares, compared to its average volume of 854,252. The stock’s 50 day moving average is $1.18 and its two-hundred day moving average is $1.49. TherapeuticsMD has a 1 year low of $0.70 and a 1 year high of $2.75.

TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.05) EPS for the quarter. The firm had revenue of $0.55 million for the quarter. TherapeuticsMD had a negative net margin of 207.77% and a negative return on equity of 14.08%.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.